Literature DB >> 15741211

Doxycycline may reduce the incidence of aneurysms in haemodialysis vascular accesses.

Charles Diskin1, Thomas J Stokes, Linda M Dansby, Lautrec Radcliff, Thomas B Carter.   

Abstract

BACKGROUND: Doxycycline can prevent aortic aneurysms through the inhibition of enzymes that degrade vessel walls. We investigated whether haemodialysis patients who had received one or more courses of doxycycline were at less risk for aneurysms in their vascular accesses than those who had received other antibiotics.
METHODS: Three hundred and eight patients undergoing chronic maintenance hemodialysis were evaluated for aneurysm formation after exposure to doxycycline or another antibiotic. Conditional forward logistical analysis using Cox proportional hazards test (SPSS) was performed to determine the potential significance of differences of aneurysm formation between the two groups.
RESULTS: Patients who had received doxycycline appeared to be at lower risk than the control group, but the effect was most obvious in those patients with synthetic grafts.
CONCLUSIONS: Doxycycline may have the ability to reduce aneurysm formation in haemodialysis vascular accesses and a large prospective study is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741211     DOI: 10.1093/ndt/gfh694

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

1.  ß-Catenin is markedly induced in a murine model of an arteriovenous fistula: the effect of metalloproteinase inhibition.

Authors:  Karl A Nath; Joseph P Grande; Lu Kang; Julio P Juncos; Allan W Ackerman; Anthony J Croatt; Zvonimir S Katusic
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-29

2.  Evolution of shear stress, protein expression, and vessel area in an animal model of arterial dilatation in hemodialysis grafts.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; James F Glockner; Debabrata Mukhopadyay
Journal:  J Vasc Interv Radiol       Date:  2010-01       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.